Lensar, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2020
November 09, 2020 at 04:59 pm EST
Share
LENSAR, Inc. announced unaudited earnings results for the third quarter and nine months ended September 30, 2020. For the quarter, the company reported total revenue was $7,145,000 against $8,068,000 a year ago. Operating loss was $4,712,000 against $5,337,000 a year ago. Net loss was $4,763,000 against $5,818,000 a year ago. Basic and diluted net loss per share attributable to common stockholders was $0.64 against $5.44 a year ago.
For the nine months, the company reported total revenue was $18,098,000 against $22,068,000 a year ago. Operating loss was $11,654,000 against $10,783,000 a year ago. Net loss was $12,946,000 against $12,189,000 a year ago. Basic and diluted net loss per share attributable to common stockholders was $4.04 against $11.39 a year ago.
LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its product portfolio consists of the LENSAR Laser System and ALLY Adaptive Cataract Treatment System (ALLY System) and its associated consumable components. The system incorporates a range of technologies designed to assist the surgeon in obtaining visual outcomes. The consumable portion of the system consists of a disposable patient interface device kit. The ALLY System is designed to combine its femtosecond laser technology features with enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room or in-office surgical suite. Its system is used across surgeons, hospital outpatient surgical facilities and ambulatory surgery centers.
LENSAR, INC. 
